immuno-oncology

News

BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.

News

Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.

News

Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer

News

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

News

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.